Oncotelic Therapeutics, Inc. (OTCQB: OTLC) announced that its proprietary PDAOAI drug discovery and development platform will be featured during the Product & Engineering keynote at Qdrant Vector Space Day 2026 in San Francisco on June 11. Company executives will join Qdrant leadership to discuss how PDAOAI, operating on Qdrant infrastructure, has helped accelerate the development of two drug candidates from concept to investigational new drug filings in less than two years, significantly reducing the time and cost traditionally associated with pharmaceutical development.
The presentation will highlight several innovations underpinning the platform, including a proprietary “manifold folding” technique designed to improve semantic retrieval accuracy and reduce large language model hallucinations, as well as the indexing of approximately 28 million PubMed biomedical abstracts on Qdrant Cloud. Oncotelic said the platform leverages advanced vector search technologies to support large-scale biomedical research and accelerate oncology drug discovery efforts.
For business and technology leaders, this development underscores the transformative potential of AI in pharmaceutical R&D. The ability to compress the timeline from concept to IND filing from the typical 5-10 years to under two years represents a paradigm shift that could dramatically lower costs and bring life-saving therapies to market faster. The PDAOAI platform’s use of vector search and manifold folding to enhance retrieval accuracy and reduce AI hallucinations addresses key challenges in deploying large language models for scientific research, making AI-driven drug discovery more reliable.
Oncotelic Therapeutics is a clinical-stage biopharmaceutical company focused on oncology and immunotherapy products, targeting high-unmet-need cancers and rare pediatric indications. The company’s CEO, Dr. Vuong Trieu, has filed over 500 patent applications and holds 75 issued patents. Beyond its internal programs, Oncotelic licenses and co-develops drug candidates through strategic partnerships and joint ventures, including a 45% interest in GMP Bio. The company’s newsroom can be accessed at https://ibn.fm/OTLC.
The full press release is available at https://ibn.fm/Ce72F. Oncotelic’s participation in Qdrant Vector Space Day 2026 highlights the growing convergence of advanced AI and biotechnology, offering a blueprint for how other companies can leverage vector databases and AI to accelerate innovation.
